Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The ability to understand and sign a written informed consent form~* 16 to 69 years of age at the time of informed consent~* Females of childbearing potential must have a negative pregnancy test and agree to avoidance of pregnancy~* Subject must show QTc \< 450 millisecond (msec) or \< 480 msec with Bundle Branch Block~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 month, or negative serum IgM-HBc antibody~* HBeAg positive; HBV-DNA \>= 6 log10 copies/mL, HBeAg negative; HBV-DNA \>= 5 log10 copies/mL~* Serum ALT \>= 31 U/L and \<= 10 × ULN~* Creatinine clearance \>= 70 mL/min~* Haemoglobin \>= 8 g/dL~* WBC \>= 1,000 /mm3~* Nucleic acid analogue naïve, i.e., no prior therapy for over 6 months in the past~* No mutation that shows resistance in LAM, ETV and/or TDF at screening~Exclusion Criteria:~* Decompensated liver disease~* Co-infection with HIV or HCV~* Autoimmune hepatitis rather than chronic hepatitis B~* Subject with serious complication~* Received or have a plan for solid organ or bone marrow transplantation~* Has proximal tubulopathy~* History of hypersensitivity to nucleoside and/or nucleotide analogues~* Evidence of hepatocellular carcinoma by diagnostic imaging at screening and/or serum α-fetoprotein \> 50 ng/mL at screening~* History of HCC~* Received any nucleoside, nucleotide, interferon or HB vaccine therapy within 24 weeks prior to initiation~* Received overdose NSAIDs, excluding temporary or topical use, within 7 days prior to initiation~* Received drugs for injection containing glycyrrhizin as the main component within 4 weeks prior to initiation~* Received drugs causing renal impairment, competitors of renal excretion, immunosuppressants, chemotherapeutics and/or corticosteroids within 8 weeks prior to initiation~* Participation in another clinical study within 6 months of study entry or planned participation in another clinical study after entry to this study~* Woman who is pregnant, lactating, possibly pregnant or planning a pregnancy during the study period~* Psychiatry disorder or cognitive disorder that may affect the subject ability to give informed consent or to follow specified study procedures~* History of alcohol or drug abuse~* Any condition or situation that may interfere with the subject's participation in the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- GSK548470 300 mg (Type: EXPERIMENTAL): GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
- ETV 0.5 mg (Type: ACTIVE_COMPARATOR): ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete